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ABSTRACT
Headache is the commonest symptom seen in both primary and secondary care. Vast majority are primary i.e. for which 
no underlying cause has been detected.  Tension Headaches, Migraine and Cluster Headaches are the most common 
primary headache disorders in the population.  Although most of the primary headache disorders can be satisfactorily 
treated with both acute and preventive medications,  those that are refractory to conventional treatment pose a great 
challenge to the headache physician.  Moreover some patients are not able to use traditional treatment due to intoler-
ance and co-morbidities.  Neurostimulation is a treatment modality that has been used in other neurological disorders 
such as movement disorders, multiple sclerosis and chronic neuropathic pain and there has been emerging evidence 
to its usefulness in primary headache disorders.  These range from being invasive treatments like deep brain stimula-
tion to minimally invasive one like occipital nerve stimulators.  Non-invasive neurostimulation is gradually emerging as 
a potential non-pharmaceutical option in managing primary headache disorders.  The article reviews the evidence of 
Neurostimulation in primary headache disorders with a view to ascertain its efficacy and safety.   
KEY WORDS: Neurostimulation, Occipital nerve stimulator, peripheral nerve stimulator, Deep brain stimulation, 
transcranial magnetic stimulation, refractory headaches
INTRODUCTION
Primary headache disorders affect almost half of population; although  primary chronic headaches occur only in around 
3%. However, these  forms of headache prove to be quite challenging  for our conventional therapeutic modalities, due 
to high prevalence of acute analgesics misuse, the relatively-unimpressive response rate to available pharmacological 
agents which reaches 50% in the best cases as well as the adverse events profile 1. Neurostimulation is a novel thera-
peutic approach, which has been tried in different neurological conditions, namely movement disorders 2, chronic 
pain3, and epilepsy4. In this  article, we review the evidence for  neurostimulation in different primary headache disor-
ders, using diverse modalities of delivery that range from  invasive ones like deep brain stimulation, less invasive 
techniques such as occipital nerve stimulation and sphenopalatine stimulation, to the non invasive modalities such as  
transcranial direct current stimulation,  transcranial magnetic stimulation and  the vagal nerve stimulation.
INVASIVE NEUROSTIMULATION
Deep brain stimulation (DBS) for Trigeminal autonomic cephalalgias (TACs):
Hypothalamic deep brain stimulation has been used as potential therapeutic target for chronic cluster headache due to 
evident hypothalamic hyperactivity during cluster attack 5. A significant responder rate (pain free or 50% responder rate) 
has been noted in about 64% across all the cases done worldwide using open-label bases6-19. A randomised, double-
blind, placebo-controlled trial, using active and sham stimulation, has failed to produce comparable results,  likely due 
to the short blinding phase, as  significant responder rate of 60% has been noted during the subsequent open-label 
phase 16. It is worth mentioning that majority of patients experienced re-emergence of cluster attacks once their stimula-
tor has stopped working which emphasise the role of stimulation as a form of symptomatic therapy. The positive results 
of DBS in treating chronic cluster headache has encouraged researchers to explore its potentials for other types of TACs 
with positive results in 3 cases of Short lasting unilateral neuralgiform headache with conjunctival injection and tearing 
(SUNCT) where patients attained significant reduction in their attacks’ frequency after at least one year of stimulation20-
22. Another positive result has been achieved with one case of chronic paroxysmal hemicranias23.
2 1 V O L .  9  ( 1 )  J A N   -   M A R   2 0 1 4P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
DBS is not a risk-free procedure, various adverse 
events have been reported including fatal intracer-
ebral haemorrhage (3%), intraoperative panic 
attacks induced by autonomic disturbance19, intraop-
erative TIA with hemiplegia lasting 5 minutes6, ocular 
movement disturbances18-19, tremor 17, and 
sneezing24. A positive effect of DBS has been an 
improved quality of sleep likely to be related to reduc-
tion of the nocturnal attacks frequency 6.
PERIPHERAL NERVE STIMULATION
The pain modulation following an electrical stimula-
tion not only has direct effects on stimulated nerve 
but also a secondary effect on the central nervous 
system. The Melzack-Wall gate control theory states 
that, ‘there is an inverse relationship between activity 
in small diameter nociceptive afferents and large 
diameter nerve fibers’. Large diameter nerve fibre 
stimulation results in reduction of the small diameter 
fiber nociceptive input and elevation of pain thresh-
olds which in turn results in pain relief 25. Hence in 
the Occipital nerve stimulation (ONS), electrical 
stimulation of C2, C3 nerve branches are expected to 
reduce the small diameter nociceptive fibers activity 
causing pain relief. According to gate control theory, 
this interaction occurs in the dorsal horn of spinal 
cord, but some studies suggest that neurostimula-
tion alters the conduction velocity and the amplitude 
of both the A-alpha and beta and the A-delta waves 
with the more slowly-conducting A-delta component 
showing the greatest changes. This direct alteration 
of peripheral nerve activity distal to the first synapse 
in the spinal cord might contribute to the mechanism 
of pain relief 26.
Peripheral nerve stimulation also has secondary 
central nervous system effects. Some of the animal 
and human studies have shown that the trigemi-
nocervical pathway is multidirectional, therefore 
activation of one part of the system results in activa-
tion of other parts. Both mechanical and electrical 
stimulation of the superior sagittal sinus results in 
activation of the neurons that extend from trigeminal 
nucleus to C1,C2 dorsal horns27, 28. The greater 
occipital nerve stimulation has also been shown to 
increase the metabolic activity of the dorsal horn at 
C1,C2 and trigeminal nucleus caudalis 29. Positron 
emission tomography (PET) studies of chronic 
migraineurs treated with bilateral ONS showed 
central nervous system effects including alteration of 
the thalamic activation that resulted in pain relief 30.
Occipital nerve stimulation (ONS)
There are three nerves that innervate occipital 
region, namely the greater occipital nerve, lesser 
occipital and least occipital nerve. The greater occipi-
tal nerve is a branch of the C2 spinal root. The lesser 
occipital nerve is composed of branches of the C2, 
C3 spinal roots. The medial branch of the posterior 
division of the C3 root gives off a branch called the 
least occipital nerve. ONS is used for many intracta-
ble headache syndromes such as occipital neuralgia, 
migraine, cluster headache and some of  less 
common conditions like SUNCT and hemicranias 
continua (HC). There is anatomical and functional 
correlation between trigeminal and cervical afferents 
called the trigeminocervical complex from the 
trigeminal caudal nucleus to at least the C2 segment 
31, hence ONS can modulate pain in the areas not 
only in the occipital nerve distribution but also in the 
trigeminal nerve distribution.
IMPLANTATION TECHNIQUES
ONS treatment was introduced by Weiner and Reed. 
There are various implantation techniques 
described32. Implantation procedure can be done 
under local or general anaesthesia. ONS is typically 
done with equipment that is normally used for spinal 
cord stimulation (SCS).  
Medication overuse headache should be ruled out 
prior to offering ONS. Often positive but transient 
response to occipital nerve blockade has been used 
prior to offering ONS trial although evidence suggests 
that this may not be a good predictor33. Many centres 
are using 5-7 day percutaneous stimulator trial to 
test the efficacy and tolerability before permanent 
implantation. The predictive values of both methods 
are questionable 34. Permanent implantation can be 
undertaken with midline or retromastoid approach 
and is usually done in two steps. The first step is 
conducted under local anaesthesia to test the stimu-
lation and optimal placement of electrodes followed 
by insertion of the remaining ONS under general 
anaesthesia. It can be successfully implanted under 
general anaesthesia as a single procedure with the 
same desired outcome 35.
There is a wide variation in the stimulation settings 
used, with the amplitude ranging from 0.1 to 10 V, 
the frequency ranging from 3 to 130 Hz and pulse 
width ranging from 90 to 450 ms36. Further studies 
are needed to establish impact of specific param-
eters on outcome. Alternatively, there are miniatur-
ized devices called ‘Bion’ which can be implanted 
over the occipital nerves 37. Recently Trentman and 
colleagues described the implantation technique and 
the stimulation parameters of the bion microstimula-
tor in nine patients with medically intractable primary 
headache disorders 38. Their results showed that the 
bion may provide effective occipital stimulation 
without requiring anchoring or tunnelling of exten-
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sions to remote power sources. Other advantage is 
reduced risk of lead migration. However it needs 
frequent recharging and may get encapsulated 
requiring increased energy to stimulate occipital 
nerve. The efficacy and safety need to be established 
with further studies.
EFFICACY AND SAFETY OF ONS
ONS has been studied in primary headache 
syndromes although it is also used in secondary 
headaches such as cervicogenic headache, post 
traumatic headache and occipital neuralgia. Popeney 
and Aloused C1 through C3 peripheral nerve stimula-
tion to treat 25 Patients who met the International 
Headache Society (IHS) criteria for episodic migraine 
refractory to pharmacological treatments. Mean 
duration of headache was 10 years (range 1-30 
years). All patients completed a successful5-7 day 
trialof outpatient stimulation with an externalised 
quadripolar electrode system before a permanent 
implant. The mean stimulation parameters were 55 
Hz frequency, 3.2 V voltage, 400 µs. 60% patients 
used the stimulator intermittently and 40% used it 
continuously. Patients were followed up for 18 
months (range 8-36 months). 88% reported at least 
50% reduction in headache frequency or severity 
after ONS was implanted. The average 3 month 
headache frequency reduced from 76 days pre ONS 
to 38 days post ONS. The Visual rating scale (VRS 
0-10) reduced from an average 9.38 to 5.72. The 
average migraine disability assessment score 
reduced from grade IV (severe) to grade I (mild). 
Medication usage reduced to less than 15 doses per 
month for residual symptoms. Complications 
included traumatic lead migration in 6, spontaneous 
migration in 3 and infection in 1 patient 39.
Oh and colleagues studied ONS in 10 patients with 
transformed migraine refractory to preventive and 
physical treatments. The mean duration of headache 
was 12 years (range 2-25 years). 9 patients had 
shown complete but transient pain relief with greater 
occipital nerve block and 1 patient had partial (80%) 
relief. 7 patients had previous success with dural 
percutaneous cylindrical electrodes that migrated. All 
10 patients were then implanted with dual paddle 
style electrodes. At one month 9 out of 10 patients 
reported more than 90% pain relief while 1 reported 
75-90% improvement. At 6 months, 7 patients 
reported more than 90% relief, 2 had 75-90% and 1 
was lost to follow up. All the patients were happy to 
undergo the operation again. Complications included 
infections in 2 patients which led to removal in 1 
patient with replacement 2 months later 40.
Schwedt and colleagues studied ONS in 8 patients 
with IHS defined chronic migraine refractory to phar-
macological therapy. Each patient had pain involving 
the C2 distribution with or without pain in the other 
regions of the head. All patients had undergone a 
5-7 day percutaneous stimulator trial prior to perma-
nent placement. 3 had unilateral stimulator and 5 
had bilateral stimulation with percutaneous cylindri-
cal leads. Patients were able to change the stimula-
tor parameters and also medication changes during 
their follow up period. At mean 18 months follow up, 
3 month headache frequency reduced from 90 to 60 
days while the VRS reduced from 6.8 to 4.5. Patients 
also reported significant reduction in disability and 
depression after the ONS operation. Complications 
include 3 patients requiring revision for lead migra-
tion and 1 required IPG revision. Neck stiffness and 
incision site pain was also reported 41.
ONS for the treatment of intractable chronic Migraine 
(ONSTIM) was a multicentre, randomised, single 
blind, controlled study by Saper et al 42. The study 
recruited 66 patients who met the revised Interna-
tional Classification of Headache Disorders (ICHD-II) 
criteria and those who had successful response to 
occipital nerve blocks. The average duration of 
migraine was 22 years (1-51 years) and chronic 
migraine for an average of 10 years prior to the study 
enrolment (range 1-30 years). Patients were 
randomised in a ratio of 2:1:1 to adjustable stimula-
tion, preset stimulation and medical treatment. The 
responder rate was defined as 50% reduction in 
headache days/month or at least 3 point drop (on 
VRS 0-10) in pain intensity at 3 months. The 
responder rate was 39% in the adjustable stimula-
tion group compared with 6% in the preset group and 
none in the medical treatment group. Complication 
of lead migration occurred in 12 of 51 patients 
(24%). It was concluded that Occipital nerve blocks 
are not predictive of ONS response. There were 
limitations to this study as blinding was not possible 
with ONS trials and paraesthesia resulting from 
stimulation and the feasibility to change the stimula-
tor parameters gave some placebo effect in adjust-
able stimulator group. However, the results overall 
suggest that ONS might represent a therapeutic 
option for some patients with chronic migraine. 
Further studies are needed to assess therapeutic 
response and complications 42. Weiner and Reed 
reported the benefit of ONS in a series of patients 
with intractable occipital neuralgia but detailed 
phenotyping in some of these patients through 
functional imaging revealed that they had chronic 
migraine 43, 44.
ONS IN CLUSTER HEADACHE
Magis et al in their study of 8 patients with medically 
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intractable cluster headache showed that treatment 
with ONS was beneficial. Weekly headache 
frequency reduced from 13.4 pre to 2.8 post ONS. 
Attack intensity reduced from 2.62 to 1.47 post ONS 
(scale of 4, 1 being mildest to 4 being worst pain). 
Majority of the patients who responded to ONS were 
able to reduce their preventative medication but only 
one was able to stop them completely. Lead 
displacement and electrode migration were reported 
in one patient each [45]. Burns et al in their study of 
14 patients with medically intractable cluster head-
ache using bilateral ONS showed variable results but 
yet demonstrating that it is fairly beneficial in 10 out 
of 14 patients. There was approximately 20-30% to 
90% improvement in headache reported in this 
study. Lead migration was reported in 29% of 
patients, other complications were muscle recruit-
ment, neck stiffness, skin discomfort, superficial 
infection, painful paraesthesias 46, 47.
Schwedt et al reported ONS use in 3 patients with 
chronic cluster headache. It was a small series and 
the efficacy of ONS was low. Headache frequency did 
not change and as a matter of fact one patient 
reported an increase in frequency. Headache severity 
in two patients had reduced from VRS 8 to 5 and 8 
to 3.5 respectively. Lead migration was the main 
adverse event 48. 
Although the above published open label studies 
show some benefit from ONS in chronic cluster 
headache, there were a few drawbacks in study 
design, patient selection, and outcome measure-
ment. Hence, Leone et al made recommendations 
on the criteria for neurostimulation in primary head-
aches. These include daily or almost daily headache 
frequency for 2 years, all the medical therapy to be 
tried for sufficient period of time unless contraindi-
cated, post implant  follow up should be at least a 
year, psychological assessment should be done prior 
to implantation surgery, patients to maintain 
prospective headache diary to document frequency, 
severity, duration of headache episodes and any 
painkillers consumed, quality of life measurements, 
self assessment of pain 49.
ONS IN HEMICRANIA CONTINUA (HC)
There are few small series suggesting some benefit in 
hemicrania continua. Schwedt el al 37 described a 
patient with HC who had discontinued indomethacin 
due to intolerance and had unilateral bion device 
implanted. There was significant improvement to 
pain free state at baseline with superimposed severe 
headaches five times in 3 months.Same group of 
colleagues treated two patients with a diagnosis of 
HC who had developed intolerance to indomethacin 
with ONS, one unilateral and one bilateral respec-
tively. At follow up, 3 month headache frequency had 
dropped from 90 days to 10 and 12 days respectively. 
Pain severity had reduced from VRS 7.5 to 3-7. Both 
patients had lead migration and one had infection 37.
Burns et al studied 6 patients with HC using bion 
device. It showed improvement in pain ranging from 
30% to 80-95%. One patient had worsening of pain 
by 20%. Adverse effects were mild and associated 
with transient overstimulation. Authors later reported 
that the one patient who got worse had chronic 
migraine after going through the medical notes and 
treatment response review 48.
ONS in Short lasting Unilateral Neuralgiform head-
ache with Conjunctival injection and Tearing (SUNCT) 
and Short lasting Unilateral Neuralgiform headache 
Attacks with cranial autonomic features (SUNA)
There is limited evidence to suggest the usefulness in 
treating SUNCT and SUNA.
Matharu and Colleagues did a study of 7 patients 
with medically intractable SUNCT and one patient 
with SUNA treated with bilateral ONS showing some 
benefit. No major side effects were reported 50.
NON-INVASIVE NEUROSTIMULATION
TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
tDCS is a non-invasive modality that uses a weak 
direct current in order to change the resting neuronal 
potential, it utilises two types of stimulation, either 
cathodal (inhibitory) or anodal (excitatory) stimula-
tions which can  modulate the function of the stimu-
lated part of the brain to achieve a desired effect. The 
effect of tDCS is thought to be restricted to the 
cerebral cortical potentials, studies have shown that 
anodal tDCS did not change the nociception-specific 
blink reflex which usually reflects brainstem electro-
physiological changes 51. Animal models of cortical 
spreading depression (CSD) (a key mechanism in 
migraine with aura) showed that this process could be 
modulated using the above mentioned technique 52.
The above mentioned findings have paved way to 
study the effect of cathodal tDCS application on the 
primary visual cortex, over 6 weeks, in 26 patients 
with migraine with aura and compare it to sham 
stimulation. Interestingly, the improvements of the 
study parameters were not statistically significant 
except for migraine intensity 53. Anodal tDCS of 
primary motor cortex has been used in different pain 
syndromes with considerable success; similar result 
were found in 13 subjects with chronic migraine, 
however it took about 3 months for pain intensity and 
period to improve 54. The largest study using tDCS 
during the migraine attack in 62 patients showed a 
reduction in pain intensity that is comparable to 
sham stimulation 55.
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TRANSCRANIAL MAGNETIC STIMULATION (TMS)
TMS has been an investigative tool in clinical neuro-
physiology for the last two decades; however its 
potential utilisation in treating migraine could revolu-
tionise the way we approach migraine treatment in 
the future. TMS utilises a rapidly changing magnetic 
field (delivered by a single or multiple pulses) to 
induce hyperpolarisation or depolarisation in the 
cerebral cortex, this is best applied to migraineur with 
aura due to CSD which is an intense depolarization of 
neuronal and glial membranes57. CSD indicates 
underlying brain hyperexcitability particularly the 
occipital cortex excitability that has been demon-
strated in migraine with aura56, 58,59. CSD in animal 
studies has shown to result in neurogenic inflamma-
tion and activation of nociceptive trigeminal afferents 
60. The animal studies with transcranial magnetic 
stimulation has shown to inhibit CSD and hence 
potentially terminate the aura and reduce the dura-
tion or severity of migraine in those with migraine 
aura 61. Commercially available devices have a 
microprocessor-controlled power source that is 
connected to an insulated wire coil. The stored 
energy is rapidly discharged through the wire coil in 
response to a trigger. This results in high current 
pulse passing through the coil creating a transient 
magnetic pulse lasting less than 1 millisecond. When 
coil is placed against the head, the transient 
magnetic field passes through the scalp and skull, 
inducing an electrical current in the underlying 
cortex. The peak magnetic field strength of a conven-
tional device is 1.5-2 Telsa comparable to fields from 
clinical magnetic resonance imaging (MRI) scanners. 
The US Food and Drug Administration characterize 
TMS by frequency. Low frequency TMS refers to a 
stimulus delivered less than 1 pulse per second and 
this is not considered to be a serious risk to health 
and safety. High frequency TMS refers to a stimulus 
that is delivered at 1 pulse per second or more and 
this is considered as a potential risk. Effect of single 
pulse stimulation has been evaluated in migraine 
using migrainous pain response and pain recurrence 
in 24 hours, In 42 patients (migraineurs with and 
without aura) using two single pulses of high and low 
intensities; migraine intensity has improved with both 
intensities and up to one third of patients did not 
experience migraine recurrence in 24 hours 62. The 
above results led to study the outcome of the same 
technique on 164 migraineurs with aura using a 
sham-controlled design; pain freedom at 2 hours 
was significantly better in the TMS arm; the head-
ache recurrence rate at 1 and 2 days after treatment 
were better in the TMS arm, however the use of 
acute analgesics and consistency of response was 
comparable between groups63. Cortical responses 
from repetitive TMS (rTMS) have been sustained for 
a longer periods than those produced by single pulse 
stimulation which found the theory bases for usage 
of rTMS in chronic pain syndromes such as fibromy-
algia and chronic migraine. Dorsolateral prefrontal 
cortex is believed to affect migrainous pain patho-
genesis negatively, which makes a target for rTMS 
studies. Results of rTMS on chronic migraine are 
inconsistent, with a sham-controlled study involving 
a total of 11 patients showed a sustained reduction 
in attacks frequency, headache index, and acute 
analgesics use for 2 months 64. However this positive 
outcome could not be attained in another sham-
controlled trial in 13 patients 65, 66.
NON CLINICAL SAFETY DATA OF TMS ON BRAIN 
AND NERVES
An animal studies have shown that there is little or 
no neural injury, 67 no delirious effect on the central 
nervous system,68 and no short or long term deficits 
in higher cerebral function or any other adverse 
events were reported.69
CLINICAL SAFETY DATA OF TMS
There are no short or long term sequelae reported 
with the use of TMS in normal individuals or those 
with neurological disorders although few adverse 
events are described. Discomfort of scalp which is 
mild to moderate in severity has been reported and it 
respond to analgesics 70. Minor adverse effects like 
dizziness, drowsiness, fatigue, increased nausea, 
itchy or tingly sensation, increased headache and 
neck pain have been reported. These adverse events 
are mild and short lasting. No serious adverse events 
have been reported 63, 71-74. One of the tolerability 
study where subjective response to TMS treatment 
was evaluated in children. They were asked to 
complete a questionnaire to rank order their TMS 
experience with few ordinary life encounters. The 
children felt TMS was less enjoyable than watching 
television but more enjoyable than a long car ride 75. 
Doses up to 12,960 pulses per day were safe and 
tolerable in healthy men and showed no effect on 
sleep 76. Overall, sTMS or rTMS is regarded as safe 
and tolerable treatment both in normal and those 
with neurological disorders provided there are no 
exclusion criteria such as presence of metal anywhere 
in the head excluding the mouth, skull defects, intra-
cardiac lines, and cardiac pacemakers 77.
POTENTIAL SAFETY CONCERNS WITH TMS
RISK OF SEIZURE
There is a hypothetical risk of inducing an epileptic 
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seizure. It can selectively activate the epileptic focus 
or foci in patients with medically intractable complex 
partial seizures 78. Schrader et al reported that crude 
risk of TMS associated seizure in patients with 
epilepsy ranged from 0.0%-2.8% for sTMS and 
0.0%-3.6% for rTMS. The nature of reported seizures 
in all cases was similar to each patient’s typical 
seizure. There were no long term sequelae79. Those 
with subcortical lesions did not have seizures 80.  
Concurrent use of medications that lower the seizure 
threshold such as tricyclic antidepressants or neuro-
leptics, has been thought to be a potential risk factor 
to induce seizure 80. Patients with stroke may have 
a risk of seizure after the use of TMS 81.
RISKS TO THE ATTACHED OR IMPLANTED ELEC-
TRONIC EQUIPMENT
The risks of sTMS to implanted or attached electronic 
devices have been studied both empirically and theo-
retically by Cadwell. In most cases, the effects of the 
magnetic field on metal objects are minimal. 
However, TMS is contraindicated in those with 
cardiac pacemakers and other implanted metallic 
objects with electrically conductive properties as it 
can dislodge the objects or induce electrical 
currents.82 Study of TMS use in patients with spinal 
cord stimulator pulse generators implanted in the 
lower abdomen has been proven safe, both when the 
device is on and off 83.
Patients with Deep Brain Stimulator (DBS) who 
received TMS treatment, no damaging stimuli to the 
brain or damage to the DBS was observed but it was 
noted that inadvertent administration of TMS directly 
over the implanted DBS could result in malfunction 
84. In those with Vagus nerve stimulator (VNS) the 
study has shown that sTMS use does not result in 
nerve stimulation or damage and the function of 
pulse generator was unaffected85.
TMS USE IN PREGNANCY
The evidence of safety of TMS use in pregnant 
women is limited. There are 2 case reports in which 
depression was treated in pregnancy with repetitive 
transcranial magnetic stimulation and there were no 
adverse effects reported in both mothers and their 
babies 86, 87. The Committee on the Possible Effects 
of Electromagnetic Fields on Biologic Systems, a 
committee of the National Research Council, 
reviewed exposure to electric and magnetic fields 
concluded that extremely low frequency electric or 
magnetic fields exposure do not affect the reproduc-
tion and development in animals especially mam-
mals [88]. It was also concluded that epidemiologic 
evidence of an association between magnetic fields 
and pregnancy outcome is not supported 89. The 
frequency of the sTMS device meets the definition of 
very low frequency (ie, <100,000 Hz) 55, 59. Further 
research studies are necessary to fully assess the 
safety data in pregnancy. Further clinical data does 
not show any significant effect of TMS on brain 
tissue, blood pressure, pulse rate, hypothalamic 
limbic structures hence no effect on cortisol or 
prolactin levels, no transient or permanent effect on 
hearing 91.
FRONTIERS OF NEUROSTIMULATION
Stimulation of the sphenopalatine ganglion, through 
its important connections to the hypothalamus and 
the trigeminovascular complex, was found to be effec-
tive in aborting around 50% of cluster and migraine 
attacks in two initial studies 92, 93 with further studies 
being conducted to verify initial findings. The stimula-
tor is implanted in the pterygopalatine fossa which 
gets activated by a hand-held controller by putting it 
on the cheek where the stimulator is located. 
Following the emergence of TMS, many novel non 
invasive modalities of neurostimulation are being 
considered e.g., Cefaly which utilises the supraorbital 
nerve stimulation for stopping migraine attacks. 
Another device, GammaCore is currently going 
through a randomised double-blind controlled trial in 
Europe on patients with cluster headache both 
during attack and as preventive treatment.  Gamma-
Core works through stimulation of vagus nerve to 
exert its effect on acute attacks. It utilises the 
findings from previous retrospective studies in 
patients with epilepsy who achieved a significant 
improvement in headaches after having a vagal nerve 
stimulator implanted for refractory epilepsy 94, 94.
CONCLUSION
The future of primary headache disorders looks prom-
ising. The invasive nature and the high cost of DBS 
and ONS makes it a very last choice for intractable 
primary headache disorders, the arrival of non-
invasive treatment may well change the way we treat 
headaches.  sTMS is currently undergoing appraisal 
through the National Institute of Clinical Excellence to 
evaluate its cost effectiveness in treating migraine 
under the National Health Service and the outcomes 
are awaited with interest.  We are aware of the post-
marketing data being collected for sTMS in the UK and 
the results will indicate its effectiveness and safety in 
the real life setting.  If successful this will open doors 
for more devices of similar nature, albeit smaller and 
cheaper to overtake pharmaceutical options. 
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